Women carrying an inherited BRCA1 or BRCA2 mutation experience similar severity, frequency, and timing of hematologic toxicity as women without a germline mutation while receiving modern day chemotherapy and supportive care for localized breast cancer. The gene discussed is BRCA2; the disease is breast carcinoma.